<DOC>
	<DOCNO>NCT03016013</DOCNO>
	<brief_summary>The purpose study initially access safety effectivity RC18 combine methotrexate ( MTX ) comparison use methotrexate alone participant moderate severe Rheumatoid Arthritis ( RA ) inadequate response MTX therapy .</brief_summary>
	<brief_title>A Study Efficacy Safety TACI-antibody Fusion Protein Injection ( RC18 ) Subjects With Inadequate Response MTX Due Treat Moderate Severe Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis adult onset RA physician define 1987 and/or 2010 ACR criterion ESR C reaction protein ( CRP ) great normal range ; Aged 1865 year old ; Consent use effective contraception study period ( woman childbearing age ) ; Patients inadequate response exist therapy least one antiTNFs Infliximab ( Remicade ) least three time , adalimumab ( Humira ) , least four time , etanercept ( Enbrel ) use least 8 week , etanercept use least 8 weeks.And Last medication time randomization 12 week ; Voluntarily sign informed consent ; Patients take MTX least 12 week screen maintain dose stability ≥7.5mg/ week ( equivalent dose ) 4 week randomization ; Treatment traditional oral diseasemodifying antirheumatic drug ( DMARD ) /immunosuppressive agent MTX within 4 week 12 week screen visit , depend DMARD ; If subject receive treatment corticosteroid , must stabilize dose ( dose prednisone ) least equal less 10mg/day 4 week ( randomization ) ; If subject receive treatment NSAIDs , must stabilize dose ( dose prednisone ) least 4 week ( randomization ) ; When patient 's condition achieve moderate severe active RA screening , define least 6/68 tenderness joint least 6/66 swollen joint . Exclusion criterion associate rheumatoid disease : 1 . The subject inflammatory arthritis ( juvenile chronic arthritis , regional enteritis ( Krohn S disease ) , ulcerative colitis , gout , active vasculitis , psoriatic arthritis ankylose spondylitis ) ; 2 . The subject secondary , non inflammatory arthritis ( osteoarthritis fibromyalgia ) , researcher think symptom arthritis interfere judgment evaluation study therapeutic effect drugs.But secondary Sjogren syndrome ( SjÖgren ) , thyroiditis without exclusion ; 3 . The subject history prosthetic joint infection , whenever infection occur , artificial joint still body ; 4 . The subject due RA and/or shoulder hand syndrome IV grade receive 3 time arthroplasty ; 5 . The subject ' Types Xray phase reach IV phase . The subject accept prohibit drug list follow table : 1 . Use analgesic ( acetaminophen / paracetamol ) within 24 hour baseline assessment ; 2. dosage regimen nonsteroidal antiinflammatory analgesic NSAIDs/COX2 inhibitor ( except acetaminophen ) occur change within 14 day baseline assessment ; 3 . The dosage oral glucocorticoid occur change within 28 day baseline assessment ; 4 . Intramuscular injection/intravenous injection/intraarticular injection glucocorticoid use within 28 day baseline assessment ; 5 . Intraarticular injection hyaluronic acid use within 28 day baseline assessment ; 6 . Tripterygium wilfordii traditional Chinese medicine treat RA use within 28 day baseline assessment . The researcher confirm subject current recent severe , progressive control heart , lung , liver , kidney important organ blood , endocrine system lesion history ; Abnormal laboratory parameter need exclude , include limited : 1 . Cr &gt; 135μmol/L 5 time upper limit laboratory reference value ; 2 . WBCs &lt; 3x 109/L ; 3. neutrophile granulocyte &lt; 1.5×109/L ; 4. hemoglobin &lt; 85g/L ; 5. platelet count &lt; 80x 109/L ; 6. total bilirubin &gt; 1.5 time upper limit laboratory reference value ; 7 . AST &gt; 2 time upper limit laboratory reference value ; 8 . ALT &gt; 2 time upper limit laboratory reference value ; 9. alkaline phosphatase &gt; 2 time upper limit laboratory reference value . HBsAgsurface antigen positive patient allow select , anti HBC single positive add HBVDNA quantitative detection , HBVDNA quantity negative regard exclusion . The antiHCV patient show positive . Infection herpes zoster HIV virus screening . The subject high risk infection ; leg ulcer , indwell catheter , persistent recurrent chest infection , completely bedridden sedentary wheelchair subject . There history chronic infection , severe lifethreatening infection ( include shingle ) within last 6 month , sign symptom screen period may indicate infection ( e.g . fever , cough ) . subject currently recently ( 30 day screen ) suffers severe viral , bacterial , fungal , parasitic infection . pregnant , lactating woman men woman birth plan past 6 month . Have history allergic reaction contrast agent parenteral administration human biological medicine . The subject receive live vaccine/attenuated vaccine within first 8 week screen know receive live vaccine/attenuated vaccine trial . Have participate clinical trial first 28 day initial screen 5 time halflife period study compound ( take time elderly ) . Patients use biological agent treatment DMARDs within three month . Active TB screening.Exception patient PPD≥15mm.But Patients anti tuberculosis treatment 3 year without relapse allow participate trial . Malignant tumor patient : patient suffer malignant tumor remove recurrence cervical carcinoma situ evidence metastatic disease basal cell squamous cell carcinoma completely remove least 3 year without recurrence participate . The patient history lymphoproliferative disease ( include lymphoma sign symptoms lymphoproliferative disease time ) . patient effective use tumor necrosis factor inhibitor ; history longterm alcohol abuse , intravenous drug abuse illicit drug abuse within 6 month . Planning surgery RA significant surgery period study . patient experience follow event within 12 week screening : myocardial infarction , unstable ischemic heart disease , stroke , New York Heart Association class IV heart failure . Patients receive interferon treatment ( interferon alpha , intron alpha , pegintron , double talon , intergen , Pegasys etc . ) within 4 week screening , expect test period need accept interferon therapy . The combined use immunosuppressive agent associate organ . transplantation allow study period . Immunosuppressive agent associate organ transplantation allow study period . Investigator consider candidate appropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>